Multiple myeloma
Until around 10 years ago, the prognosis for people with multiple myeloma was poor. It’s still the second most common blood cancer after leukaemia – but thanks to better treatments, the situation is improving.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from GlaxoSmithKline in producing this Outlook. The sponsor retains sole responsibility for the following message.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics, and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody-drug conjugates and cells, either alone or in combination.
